IBL-202 and venetoclax are synergistic against OSU-CLL-TP53ko cells. (A) Dose responses for IBL-202 or venetoclax as single agents toward wild-type (WT) OSU-CLL and OSU-CLL-TP53ko cells. (B) CI plot and isobolograms for IBL-202 and venetoclax in combination against WT and OSU-CLL-TP53ko cells. CI values <1 indicate synergy. (C) Cell-cycle analyses performed on control and OSU-CLL-TP53ko cells after treatment for 72 hours with the indicated dose of each drug. (D) Proliferation analysis of control and OSU-CLL-TP53ko cells treated with IBL-202 or venetoclax alone or in combination over a 72-hour time course. MFI, mean fluorescence intensity.